New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Coronado Biosciences Inc (NASDAQ:CNDO), Opexa Therapeutics Inc (NASDAQ:OPXA), Axcelis Technologies Inc (NASDAQ:ACLS), Gevo, Inc (NASDAQ:GEVO)
Coronado Biosciences Inc (NASDAQ:CNDO) showed a volume of 1.19 million shares by the end of last trade whereas the average volume of the stock remained 2.43 million shares. The stock opened the session at $2.83 but then moved to $2.70. At that price, the stock showed a negative performance of -4.59%. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company’s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn’s disease (Crohn’s),
Will CNDO Get Buyers Even After The Recent Rally? Find Out Here
Opexa Therapeutics Inc (NASDAQ:OPXA) opened the session at $1.94 and closed the session at $1.94. The stock showed a positive performance of 2.11% in previous trading session. Traded with volume of 1.18 million shares in the prior session and the average volume of the stock remained 538,363.00 shares. Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company’s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS.
For How Long OPXA will fight for Profitability? Read This Trend Analysis report
Axcelis Technologies Inc (NASDAQ:ACLS) opened the session at $2.43 and closed the session at $2.38. The stock showed a negative performance of -1.24% in previous trading session. Traded with volume of 1.17 million shares in the prior session and the average volume of the stock remained 549,599.00 shares. The beta of the stock remained 2.35. Axcelis Technologies, Inc. (Axcelis) designs, manufactures and services ion implantation, dry strip and other processing equipment used in the fabrication of semiconductor chips. The Company sells to semiconductor chip manufacturers worldwide. The ion implantation business comprised approximately 76.7% of its revenue during the year ended December 31, 2012, with the remaining 23.3% of revenue derived from its dry strip and other processing systems. In addition to equipment,
Why Should Investors Buy ACLS After the Recent Fall? Just Go Here and Find Out
Gevo, Inc (NASDAQ:GEVO) the stock decreased -2.55% and finished the session at $1.34. Traded with volume of 1.17million shares in the prior session and the average volume of the stock remained 1.85 million shares. Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services.
Will GEVO Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)